{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:56:43Z","timestamp":1793699803167,"version":"4.5.1"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T00:00:00Z","timestamp":1256947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>(<jats:italic>Cancer Sci<\/jats:italic> 2010; 101: 815\u2013819)<\/jats:p><jats:p>Recently, it was observed that nestin is preferentially expressed in basal\/myoepithelial cells of the mammary gland, and that this intermediate filament may be used as a myoepithelial marker. However, the clinical and prognostic implications of nestin as a marker for breast cancer are still unclear. We examined mastectomy specimens from 150 breast cancers and matching, adjacent non\u2010cancerous tissues using immunohistochemistry and western blotting. Overall, triple\u2010negative breast cancers \u2013 that is, breast cancers that do not express estrogen receptors (ER), progesterone receptors (PR), or human epidermal growth factor receptor 2 (HER2\/neu) \u2013 had higher expression rates for nestin than the other breast cancers (57.14%<jats:italic>vs<\/jats:italic> 9.30%; <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). In triple\u2010negative breast cancers, significantly increased nestin expression rates were observed in patients with lymph node metastasis compared with those without node metastasis (25.00%<jats:italic>vs<\/jats:italic> 76.92%; <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.032). A similar phenomenon was observed for invasive ductal carcinomas compared with ductal carcinoma <jats:italic>in situ<\/jats:italic> (16.67%<jats:italic>vs<\/jats:italic> 73.33%; <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.046). Nestin expression was also found to be significantly related to ER, PR, and P53 expression (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.05). Nestin expression was associated with both shorter breast cancer\u2010specific survival and poor relapse\u2010free survival in the lymph node\u2010positive group (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.028 and <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.012 respectively). After Cox regression was carried out, nestin was not shown to be an independent prognostic factor for breast cancer. These findings substantiate the possibility of using nestin as a marker for triple\u2010negative breast cancer. Triple\u2010negative breast cancer progression is associated with nestin; however, the underlying mechanisms of this relationship require further investigation.<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01422.x","type":"journal-article","created":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T13:56:57Z","timestamp":1256997417000},"page":"815-819","source":"Crossref","is-referenced-by-count":47,"title":["Clinical implications for nestin protein expression in breast cancer"],"prefix":"10.1111","volume":"101","author":[{"given":"Caigang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruishan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2005.01.002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2008.04.002"},{"key":"e_1_2_6_4_2","first-page":"695","article-title":"Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER\u20102\/neu expression delineate different subgroups in ductal carcinoma in situ of the breast","volume":"12","author":"Rody A","year":"2004","journal-title":"Oncol Rep"},{"key":"e_1_2_6_5_2","first-page":"185","article-title":"Tamoxifen metabolism and its effect on endocrine treatment of breast cancer","volume":"7","author":"Briest S","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3087"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2008.01.007"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.3.289"},{"key":"e_1_2_6_9_2","first-page":"593","article-title":"Identification of neovasculature using nestin in colorectal cancer","volume":"3","author":"Teranishi N","year":"2007","journal-title":"Int J Oncol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4571"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2008.058750"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.01.006"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2249"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/172460080902400106"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0230"},{"key":"e_1_2_6_16_2","first-page":"133","article-title":"Predicting endocrine therapy responsiveness in breast cancer","volume":"23","author":"Ma CX","year":"2009","journal-title":"Oncology"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4144-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.103.2.589"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01422.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01422.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:10:01Z","timestamp":1697429401000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01422.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,17]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01422.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01422.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,17]]}}}